Phase 1/1b study of novel oral selective estrogen receptor degrader (SERD) LSZ102 in combination with alpelisib (BYL719) in estrogen receptor-positive (ER plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) with progression on endocrine therapy (ET) Meeting Abstract
| Authors: | Curigliano, G.; Cresta, S.; Yap, Y. S.; Juric, D.; Duhoux, F. P.; Terret, C.; Takahashi, S.; Layman, R. M.; Kundamal, N.; Baldoni, D.; Liao, S.; Crystal, A.; Jhaveri, K. |
| Abstract Title: | Phase 1/1b study of novel oral selective estrogen receptor degrader (SERD) LSZ102 in combination with alpelisib (BYL719) in estrogen receptor-positive (ER plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) with progression on endocrine therapy (ET) |
| Meeting Title: | 41st Annual San Antonio Breast Cancer Symposium (SABCS) |
| Journal Title: | Cancer Research |
| Volume: | 79 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2018 Dec 4-10 |
| Meeting Location: | San Antonio, TX |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2019-02-01 |
| Language: | English |
| ACCESSION: | WOS:000478677000099 |
| DOI: | 10.1158/1538-7445.Sabcs18-ot1-03-01 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: OT1-03-01 -- Source: Wos |
